---
figid: PMC9019265__cdr-4-356.fig.1
figtitle: Statins and endocrine resistance in breast cancer
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC9019265
filename: cdr-4-356.fig.1.jpg
figlink: /pmc/articles/PMC9019265/figure/fig1/
number: F1
caption: Mechanisms of endocrine resistance in breast cancer. Tamoxifen resistance
  has been associated with increased expression of the transcription factor SREBF
  (A). SREBF activates the transcription of mevalonate pathway (MVP) genes, like HMGCR
  (B). Activation of the mevalonate pathway induces prenylation of small GTPases such
  as Rho, Ras, or Rab (C). Ras prenylation leads to phosphorylation of PI3K (D), which
  activates Akt and mTOR to phosphorylate the residue, Ser167, of the estrogen receptor
  (ERa), which decreases sensitivity to tamoxifen (E). This leads to continued Era-derived
  transcription and phosphorylation of Rb, accelerating G1/S cell cycle transition
  (F). Ras phosphorylation also activates MEK (G), which activates ERK1/2. The latter
  is associated to a senescence-associated secretory phenotype (SASP) (H). Created
  with Biorender.com.
papertitle: Statins and endocrine resistance in breast cancer.
reftext: Tara Hyder, et al. Cancer Drug Resist. 2021;4(2):356-364.
year: '2021'
doi: 10.20517/cdr.2020.112
journal_title: Cancer Drug Resistance
journal_nlm_ta: Cancer Drug Resist
publisher_name: OAE Publishing Inc.
keywords: Statin | HMGCR | endocrine resistance | autophagy | PI3K | mTOR
automl_pathway: 0.9628951
figid_alias: PMC9019265__F1
figtype: Figure
redirect_from: /figures/PMC9019265__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9019265__cdr-4-356.fig.1.html
  '@type': Dataset
  description: Mechanisms of endocrine resistance in breast cancer. Tamoxifen resistance
    has been associated with increased expression of the transcription factor SREBF
    (A). SREBF activates the transcription of mevalonate pathway (MVP) genes, like
    HMGCR (B). Activation of the mevalonate pathway induces prenylation of small GTPases
    such as Rho, Ras, or Rab (C). Ras prenylation leads to phosphorylation of PI3K
    (D), which activates Akt and mTOR to phosphorylate the residue, Ser167, of the
    estrogen receptor (ERa), which decreases sensitivity to tamoxifen (E). This leads
    to continued Era-derived transcription and phosphorylation of Rb, accelerating
    G1/S cell cycle transition (F). Ras phosphorylation also activates MEK (G), which
    activates ERK1/2. The latter is associated to a senescence-associated secretory
    phenotype (SASP) (H). Created with Biorender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ESR1
  - ERAL1
  - RENBP
  - SUGP1
  - TAM
  - STIM1
  - ASPRV1
  - MAPK3
  - MAPK1
  - SREBF1
  - SREBF2
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - RAB5A
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RAB27B
  - AGFG1
  - RAB10
  - RAB11A
  - RAB11B
  - RAB12
  - RAB13
  - RAB14
  - RAB15
  - RAB17
  - RAB18
  - RAB19
  - RAB1A
  - RAB1B
  - RAB1C
  - RAB20
  - RAB21
  - RAB22A
  - RAB23
  - RAB24
  - RAB25
  - RAB26
  - RAB27A
  - RAB28
  - RAB2A
  - RAB2B
  - RAB30
  - RAB31
  - RAB32
  - RAB33A
  - RAB33B
  - RAB34
  - RAB35
  - RAB36
  - RAB37
  - RAB38
  - RAB39A
  - RAB39B
  - RAB3A
  - RAB3B
  - RAB3C
  - RAB3D
  - RAB40A
  - RAB40AL
  - RAB40B
  - RAB40C
  - RAB41
  - RAB42
  - RAB43
  - RAB44
  - RAB4A
  - RAB4B
  - RAB5B
  - RAB5C
  - RAB6A
  - RAB6B
  - RAB6C
  - RAB7A
  - RAB7B
  - RAB29
  - RAB8A
  - RAB8B
  - RAB9A
  - RAB9B
  - RABL2A
  - RABL2B
  - RABL3
  - IFT22
  - RHO
  - RHOD
  - RHOA
  - RHOB
  - RHOC
  - era
  - rb
  - Rbp
  - Rbp9
  - Tbp
  - br
  - PolG1
  - pyd
  - rl
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Mtor
  - Tor
  - Rab11
  - Rab5
  - Dsor1
  - Mtk
  - rab
  - rho
  - Bx
  - Rho1
  - Lcp65Ab1
---
